fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA accepts sNDA for Nubeqa (darolutamide) plus ADT to treat metastatic hormone-sensitive prostate cancer – Bayer

Written by | 29 Nov 2024

Bayer  announced that the  FDA has accepted the company’s supplemental new drug application (sNDA) for the oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) in combination with androgen deprivation… read more.

Application submitted for third indication of darolutamide in the EU – Bayer

Written by | 19 Oct 2024

Bayer announced the submission of an application to the European Medicines Agency (EMA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use… read more.

Talzenna (talazoparib) + Xtandi (enzalutamide) prolongs overall survival in phase III TALAPRO-2 trial for prostate cancer

Written by | 16 Oct 2024

Pfizer Inc. announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna  (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor,… read more.

The Stockholm3 prostate cancer test is effective for diverse ethnic groups and could reduce unnecessary biopsies

Written by | 30 Jul 2024

The Stockholm3 blood test is equally precise at detecting prostate cancer in different ethnic groups, and it could reduce unnecessary biopsies by about half, researchers reported on July… read more.

Darolutamide meets primary endpoint in phase III ARANOTE trial in men with metastatic hormone-sensitive prostate cancer – Bayer + Orion

Written by | 18 Jul 2024

The Phase III ARANOTE trial, investigating darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), has met its primary endpoint of rPFS.( radiological progression-free survival). Darolutamide… read more.

The Lancet: Prostate cancer cases expected to double worldwide between 2020 and 2040, new analysis suggests

Written by | 14 Apr 2024

Cases of prostate cancer are projected to double from 1.4 million per year in 2020 to 2.9 million per year by 2040, with low- and middle-income countries (LMICs)… read more.

Positive CHMP opinion for Xtandi (enzaltamide) in additional recurrent early prostate cancer treatment setting – Astellas

Written by | 30 Mar 2024

Astellas Pharma Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of Xtandi (enzalutamide)… read more.

Drug-pricing program improved prostate cancer treatment adherence

Written by | 26 Mar 2024

Prostate cancer patients receiving care at hospitals that are part of a special drug-pricing program were more likely to stick to their prescription drug therapy than patients at… read more.

CHMP positive for Talzenna + Xtandi (talazoparib + enzalutamide) to treatmetastatic castration-resistant prostate cancer – Pfizer

Written by | 17 Nov 2023

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Talzenna…. read more.

Enzalutamide improves outcomes in in biochemically recurrent prostate cancer

Written by | 21 Oct 2023

In patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus standard-treatment leuprolide is superior to leuprolide monotherapy for metastasis-free survival. And enzalutamide monotherapy is also superior to… read more.

Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer

Written by | 12 Oct 2023

Novartis will present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, highlighting latest developments from across its oncology… read more.

Men who trust their doctors, receive adequate time and general information about prostate cancer screening are more likely to have productive discussions

Written by | 25 Sep 2023

Members of the University of Ottawa Department of Family Medicine conducted a scoping review to understand men’s communication preferences when they discuss prostate cancer screening with their doctors…. read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.